BTIG raised the firm's price target on Sophia Genetics to $8 from $7 and keeps a Buy rating on the shares. After having recently hosted two days of investor meetings with Sophia Genetics' President and soon-to-be CEO Ross Muken, CFO George Cardoza and Head of Strategy Kellen Sanger, the firm reports that management "signaled confidence across the business."
